title: Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
abstract: OBJECTIVE
  To investigate the best standardized uptake value (SUV) index for differentiation of adrenal metastases from adrenocortical adenomas using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT).
  
  
  METHODS
  A total of 129 patients (82 males and 47 females; mean age 65.4 years) with extra-adrenal primary malignancies who had known or suspected adrenal lesions underwent FDG PET/CT examinations for detection, staging, re-staging, or recurrence of tumor. Among these patients, 45 adrenal lesions (22 adenomas and 23 metastases) in 41 patients were evaluated. The maximum SUVs for adrenal lesions (adrenal SUVmax) and mean liver and spleen SUVs were recorded, and the ratio of the adrenal SUVmax to the mean liver SUV (adrenal-to-liver SUV ratio) and that of the adrenal SUVmax to the mean spleen SUV (adrenal-to-spleen SUV ratio) were obtained. Diagnostic performances for the adrenal SUVmax, adrenal-to-liver SUV ratio, and adrenal-to-spleen SUV ratio were compared.
  
  
  RESULTS
  The mean adrenal SUVmax, adrenal-to-liver SUV ratio, and adrenal-to-spleen SUV ratio were higher for adrenal metastases (8.4 ± 3.8, 3.0 ± 1.3, and 4.0 ± 1.9, respectively) than for adrenocortical adenomas (2.9 ± 1.0, 0.9 ± 0.3, and 1.3 ± 0.3, respectively) (P < 0.001). The area under the curve was higher for the adrenal-to-liver SUV ratio (0.99) than for the adrenal SUVmax (0.96) and adrenal-to-spleen SUV ratio (0.98). In the differentiation of adrenocortical adenomas and adrenal metastases, an adrenal-to-liver SUV ratio cutoff value of 1.37 yielded a sensitivity of 96% and specificity of 100%.
  
  
  CONCLUSIONS
  In FDG PET/CT analysis, the adrenal-to-liver SUV ratio had a greater ability to differentiate adrenocortical adenomas and adrenal metastases than did the adrenal SUVmax or adrenal-to-spleen SUV ratio.
authors.affiliation: Department of Radiology, Gifu Central Hospital, 3-25 Kawabe, Gifu, 501-1198, Japan. haruwow860@yahoo.co.jp
authors.forename: Haruo
authors.initials: H
authors.lastname: Watanabe
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kanematsu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Goshima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kondo
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawada
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Noda
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Moriyama
mesh_terms: D000236:Adenoma / Q000473:pathology*; D000310:Adrenal Gland Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000556:secondary*; D000311:Adrenal Glands / Q000000981:diagnostic imaging / Q000378:metabolism; D000368:Aged; D001692:Biological Transport; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D012372:ROC Curve; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18